Immunocore Holdings plc Other Noncash Income (Expense)
Immunocore Holdings plc (IMCR) reported Other Noncash Income (Expense) of -$1.08 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-06
- Immunocore Holdings plc other noncash income (expense) for the quarter ending 2026-06-30 was -$546.00K.
- Immunocore Holdings plc other noncash income (expense) for the quarter ending 2026-03-31 was -$534.00K.
- Immunocore Holdings plc other noncash income (expense) for the quarter ending 2025-12-31 was -$537.00K.
- Immunocore Holdings plc other noncash income (expense) for the quarter ending 2025-09-30 was -$527.00K.
- Immunocore Holdings plc other noncash income (expense) for fiscal 2025 was -$2.11M.
- Immunocore Holdings plc other noncash income (expense) for fiscal 2024 was -$1.84M.
- Immunocore Holdings plc other noncash income (expense) for fiscal 2023 was -$412.00K, a 10400.00% decline from fiscal 2022.
- Immunocore Holdings plc other noncash income (expense) for fiscal 2022 was $4.00K.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$546.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.08M 10-Q · filed 2026-08-06 | -$1.62M derived: sum of 3 quarters · filed 2026-08-06 | -$2.14M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$534.00K 10-Q · filed 2026-05-06 | -$1.07M derived: sum of 2 quarters · filed 2026-05-06 | -$1.60M derived: sum of 3 quarters · filed 2026-05-06 | -$2.14M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$537.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$1.06M derived: sum of 2 quarters · filed 2026-02-25 | -$1.60M derived: sum of 3 quarters · filed 2026-08-06 | -$2.11M 10-K · filed 2026-02-25 |
| 2025-09-30 | -$527.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.07M derived: sum of 2 quarters · filed 2026-08-06 | -$1.58M 10-Q · filed 2025-11-06 | -$1.88M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$540.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.05M 10-Q · filed 2026-08-06 | -$1.35M derived: sum of 3 quarters · filed 2026-08-06 | -$1.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$509.00K 10-Q · filed 2026-05-06 | -$812.00K derived: sum of 2 quarters · filed 2026-05-06 | -$1.40M derived: sum of 3 quarters · filed 2026-05-06 | -$2.35M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$303.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$887.00K derived: sum of 2 quarters · filed 2026-02-25 | -$1.84M derived: sum of 3 quarters · filed 2026-02-25 | -$1.84M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$584.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.54M derived: sum of 2 quarters · filed 2025-11-06 | -$1.53M 10-Q · filed 2025-11-06 | -$1.75M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$953.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$951.00K 10-Q · filed 2025-08-07 | -$1.17M derived: sum of 3 quarters · filed 2026-02-25 | -$1.36M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $2.00K 10-Q · filed 2025-05-07 | -$213.00K derived: sum of 2 quarters · filed 2026-02-25 | -$410.00K derived: sum of 3 quarters · filed 2026-02-25 | -$410.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$215.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$412.00K derived: sum of 2 quarters · filed 2026-02-25 | -$412.00K derived: sum of 3 quarters · filed 2026-02-25 | -$412.00K 10-K · filed 2026-02-25 |
| 2023-09-30 | -$197.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$197.00K derived: sum of 2 quarters · filed 2024-11-06 | -$197.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $4.00K 10-K · filed 2025-02-26 | |||
| 2021-12-31 | -$222.00K 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |